Day One Biopharmaceuticals (NASDAQ:DAWN) Rating Lowered to Hold at Zacks Research

Day One Biopharmaceuticals (NASDAQ:DAWN) was downgraded by Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

A number of other analysts have also commented on DAWN. Weiss Ratings restated a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research note on Monday, December 29th. TD Cowen began coverage on Day One Biopharmaceuticals in a research note on Tuesday, January 13th. They set a “buy” rating and a $34.00 price target for the company. HC Wainwright reduced their target price on shares of Day One Biopharmaceuticals from $25.00 to $22.00 and set a “buy” rating for the company in a research note on Wednesday. Piper Sandler raised their price target on shares of Day One Biopharmaceuticals from $25.00 to $26.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. Finally, Wedbush upped their price objective on shares of Day One Biopharmaceuticals from $29.00 to $30.00 and gave the stock an “outperform” rating in a research report on Wednesday. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Day One Biopharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $26.14.

Day One Biopharmaceuticals Trading Down 2.6%

Shares of NASDAQ DAWN opened at $10.65 on Wednesday. Day One Biopharmaceuticals has a 1-year low of $5.64 and a 1-year high of $13.20. The firm has a market capitalization of $1.10 billion, a P/E ratio of -10.34 and a beta of -1.26. The firm’s 50-day moving average price is $10.69 and its 200-day moving average price is $8.77.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). Day One Biopharmaceuticals had a negative return on equity of 23.43% and a negative net margin of 67.85%.The firm had revenue of $53.72 million for the quarter, compared to analyst estimates of $49.81 million. Equities research analysts forecast that Day One Biopharmaceuticals will post -0.72 EPS for the current year.

Insiders Place Their Bets

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 15,459 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total transaction of $179,324.40. Following the completion of the transaction, the chief executive officer directly owned 204,603 shares of the company’s stock, valued at approximately $2,373,394.80. This represents a 7.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Lauren Merendino sold 5,814 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total value of $67,442.40. Following the completion of the sale, the insider owned 60,157 shares in the company, valued at approximately $697,821.20. The trade was a 8.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 36,461 shares of company stock valued at $422,948 in the last quarter. 6.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Several institutional investors have recently added to or reduced their stakes in DAWN. Vanguard Group Inc. boosted its holdings in Day One Biopharmaceuticals by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 6,282,376 shares of the company’s stock worth $58,552,000 after buying an additional 101,047 shares during the period. Vestal Point Capital LP grew its stake in Day One Biopharmaceuticals by 94.4% during the fourth quarter. Vestal Point Capital LP now owns 5,200,000 shares of the company’s stock valued at $48,464,000 after acquiring an additional 2,525,000 shares in the last quarter. Deerfield Management Company L.P. grew its stake in Day One Biopharmaceuticals by 26.4% during the third quarter. Deerfield Management Company L.P. now owns 4,705,413 shares of the company’s stock valued at $33,173,000 after acquiring an additional 982,282 shares in the last quarter. State Street Corp increased its holdings in Day One Biopharmaceuticals by 32.4% during the 4th quarter. State Street Corp now owns 4,289,566 shares of the company’s stock worth $39,979,000 after acquiring an additional 1,049,122 shares during the period. Finally, Franklin Resources Inc. lifted its stake in Day One Biopharmaceuticals by 2.0% in the 2nd quarter. Franklin Resources Inc. now owns 4,097,625 shares of the company’s stock worth $26,635,000 after purchasing an additional 79,255 shares in the last quarter. 87.95% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Day One Biopharmaceuticals

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Wedbush raised its price target to $30 and kept an “outperform” rating, signaling strong upside potential from current levels and offering a bullish institutional endorsement. Wedbush PT Raise
• Positive Sentiment: Revenue beat — Q4 revenue came in above consensus (company reported ~$53.7M vs est. ~$49.8M), described as record revenue growth, which supports top‑line momentum and future commercial prospects. Earnings Highlights
• Neutral Sentiment: Analyst roundup pieces summarizing multiple firms’ views are circulating, providing varied takes that can sustain volatility as investors parse differing price targets and ratings. Analyst Roundup
• Neutral Sentiment: Short-interest report shows 0 shares noted for the period (data appears anomalous), so current short-interest metrics provide no clear signal and should be treated cautiously.
• Neutral Sentiment: Earnings materials and full transcripts are available for deeper review (presentation and call transcripts), useful for investors who want management commentary on guidance, commercial rollout and cost trajectory. Earnings Presentation
• Negative Sentiment: EPS missed expectations — Q4 GAAP loss was $0.21 per share vs. the consensus loss of $0.17, highlighting ongoing profitability pressure and contributing to near-term downside risk. EPS Miss Coverage
• Negative Sentiment: Some analysts trimmed price targets (Needham cut to $17; HC Wainwright lowered to $22) even while keeping “buy” ratings — these reductions reduce consensus upside and can weigh on sentiment despite revenue strength. Analyst PT Changes

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.